These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23573566)

  • 1. Glycoprotein IIb/IIIa inhibitors.
    Lincoff AM
    J Invasive Cardiol; 2004 Jul; 16(7 Suppl):11S-16S. PubMed ID: 23573566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
    Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 4. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of abciximab in interventional cardiology.
    Chronos N; Vahanian A; Betriu A; Emanuelsson H; Goldberg S; Gulba D; van Hout BA
    Eur Heart J; 1998 Apr; 19 Suppl D():D31-9. PubMed ID: 9597520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer therapeutic concept in antiplatelet aggregation inhibition--GPIIb-IIIa receptor antagonists.
    Malhotra S; Mishra NK; Sinha RS; Gupta B
    J Assoc Physicians India; 2000 Mar; 48(3):329-34. PubMed ID: 11229122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein IIb/IIIa antagonists: new developments.
    Zeymer U; Zahn R
    Hamostaseologie; 2009 Nov; 29(4):334-7; quiz 338. PubMed ID: 19882074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing and administration of ReoPro (c7E3 Fab).
    Tcheng JE
    J Invasive Cardiol; 1994; 6 Suppl A():29A-33A; discussion 51A-54A. PubMed ID: 10155091
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy.
    Coller BS
    Circulation; 1997 Dec; 96(11):3828-32. PubMed ID: 9403602
    [No Abstract]   [Full Text] [Related]  

  • 11. Safe use of platelet GP IIb/IIIa inhibitors.
    Ferguson JJ; Kereiakes DJ; Adgey AA; Fox KA; Hillegass WB; Pfisterer M; Vassanelli C
    Eur Heart J; 1998 Apr; 19 Suppl D():D40-51. PubMed ID: 9597521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glycoprotein IIb/IIIa receptor inhibitors].
    Bornkessel B
    Med Monatsschr Pharm; 1996 Dec; 19(12):356-8. PubMed ID: 9082150
    [No Abstract]   [Full Text] [Related]  

  • 13. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era?
    Roffi M; Mukherjee D
    Eur Heart J; 2008 Feb; 29(4):429-31. PubMed ID: 18276614
    [No Abstract]   [Full Text] [Related]  

  • 16. Local delivery of glycoprotein IIb/IIIa receptor inhibitors using drug eluting stents.
    Gershlick AH
    Semin Interv Cardiol; 1998; 3(3-4):185-90. PubMed ID: 10406691
    [No Abstract]   [Full Text] [Related]  

  • 17. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 18. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic dissolution of an intracoronary thrombus by prolonged intravenous platelet glycoprotein IIb/IIIa antagonism.
    Radke PW; Janssens U; Schwarz ER; vom Dahl J
    J Invasive Cardiol; 1999 Nov; 11(11):679-81. PubMed ID: 10745462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of abciximab in interventional cardiology.
    Chronos N; Vahanian A; Betriu A; Emanuelsson H; Goldberg S; Gulba D; van Hout BA
    Am Heart J; 1998 Apr; 135(4):S67-76. PubMed ID: 9539497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.